• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Provocative poster sessions abound at the SPD 2022 47th Annual Meeting

Article

You will find dermatologic studies from the rare (annual erythema of infancy) to the common (atopic dermatitis) and lots in between at the poster sessions at this year's SPD 2022 47th Annual Meeting in Indianapolis, Indiana.

Dermatology experts that span the United States, Germany, France, and elsewhere offer exciting and novel poster sessions at this year's medical conference.

During these sessions, you can discover a number of studies on the burden of atopic dermatitis in infants and preschoolers; an algorithm approach to identify teenagers with hidradenitis suppurativa at risk for poor school performance; investigations of Crohn's disease in pyoderma gangrenosum management, and drug reactions among pediatric allogeneic hematopoietic stem call transplantation patients.

Pediatric teledermatology in rural Malawi, an analysis of pediatric lichen nitidus, systematic review of mental health comorbidties in juvenile localized scleroderma, and even a look at a pilot randomized controlled trial on the effect of virtual reality on pain and anxiety levels during dermatologic procedures are also on view.

The sessions span themes of what's new in biologics, psychosocial concerns in dermatology for children and adolescents, and both rare and common dermatologic disorders in the pediatric population.

The robust number of available poster sessions point to just how busy a year it has been in the field of pediatric dermatology.

Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.